(19)
(11) EP 4 255 467 A1

(12)

(43) Date of publication:
11.10.2023 Bulletin 2023/41

(21) Application number: 21830575.3

(22) Date of filing: 06.12.2021
(51) International Patent Classification (IPC): 
A61K 38/24(2006.01)
A61P 35/00(2006.01)
 G01N 33/48(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 38/24; G01N 33/57415; G01N 2800/52; G01N 2800/50
(86) International application number:
PCT/US2021/061956
(87) International publication number:
WO 2022/125417 (16.06.2022 Gazette 2022/24)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 07.12.2020 US 202063122023 P
07.12.2020 EP 20212210

(71) Applicants:
  • Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center
    Philadelphia, PA 19111-2497 (US)
  • Universiteit Gent
    9000 Gent (BE)

(72) Inventors:
  • RUSSO, Jose
    Philadelphia, Pennsylvania 19111-2497 (US)
  • DEPYPERE, Herman
    9000 Ghent (BE)
  • SU, Yanrong
    Philadelphia, Pennsylvania 19111-2497 (US)
  • DANG, Nhi
    Philadelphia, Pennsylvania 19111-2497 (US)
  • JANSSENS, Jaak
    9000 Ghent (BE)

(74) Representative: Hadfield, Andrea et al
Kilburn & Strode LLP Lacon London 84 Theobalds Road
London WC1X 8NL
London WC1X 8NL (GB)

   


(54) TREATMENT OF FEMALES HAVING BRCA1/2 MUTATIONS WITH HUMAN CHORIONIC GONADOTROPIN TO REDUCE THE RISK OF DEVELOPING BREAST CANCER